Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell(TM)) Across Multiple Ischemic and Vascular Indications Simultaneously
Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to ann
Biotechnology, Pharmaceuticals, Health
2025-09-23 12:22 PM EDT | Hemostemix Inc.
Neural's Partner Hanf.com Expands Retail Footprint with 17th Store Opening Near Munich
Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of its 17t
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-09-23 12:16 PM EDT | Neural Therapeutics Inc.
Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin
Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to share the interview of Dr. Amie Phinney, Defence's director, strategy & business advisor, with Ellis Martin on Money Talk Radio.
Biotechnology, Pharmaceuticals, Health
2025-09-23 9:15 AM EDT | Defence Therapeutics Inc.
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2025
Biotechnology, Pharmaceuticals
2025-09-23 8:30 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-23 7:45 AM EDT | Phio Pharmaceuticals Corp.
Envoy Medical Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - September 22, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,908,402 shares of its Class A common stock at a purchase price of $1.31 per share of Class A common stock, in a registered direct offering priced at-the-market under Nasd
Biotechnology, Healthcare and Hospitals
2025-09-22 8:00 AM EDT | Envoy Medical, Inc.
BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction
Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.
Biotechnology, Pharmaceuticals, Health
2025-09-22 6:32 AM EDT | BioHarvest Sciences Inc.
Scryb Announces Upsize of Private Placement Following Strong Investor Demand
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb" or the "Company") is pleased to announce that due to strong market demand, it intends to upsize its previously announced non-brokered private placement (the "Offering") to $1,500,000, or 15,000,000 units of the Company (each, a "Unit") at a price of $0.10 per Unit. Each Unit will consist of one common share (a "Common Share") and one half of one common share p
Biotechnology, Healthcare and Hospitals, Health
2025-09-19 6:59 PM EDT | Scryb Inc.
PreveCeutical Announces Mailing and Filing of Annual General and Special Meeting Materials in Connection with a Proposed Arrangement with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 19, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that further to its News Release of September 4, 2025, it has filed with the applicable Canadian securities regulatory authorities the management information circular dated September 9, 2025 and related meeting materials of the Company (the "Meeting Materials") for use at the annual ge
Biotechnology, Pharmaceuticals, Health
2025-09-19 6:00 PM EDT | PreveCeutical Medical Inc.
Britannia Life Sciences Inc. Delays Closing of Debenture Offering
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Britannia Life Sciences Inc. (CSE: BLAB) ("Britannia" or the "Company") announced today that the closing of its previously announced non-brokered private placement offering of unsecured debentures (the "Debentures") for gross proceeds of up to CAD$10 million (the "Offering") will be delayed until September 30, 2025 or such other date as the Company and subscribers may agree. The Offering was initiall
Biotechnology, Household / Consumer / Cosmetics, Health, Cannabis Ancillary Service Provider
2025-09-19 5:00 PM EDT | Britannia Life Sciences Inc
Telo Genomics Highlights New MRD Methodology at The 2025 International Myeloma Society Meeting
Toronto, Ontario--(Newsfile Corp. - September 19, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company has presented a poster abstract on minimal residual disease ("MRD") during the 22nd International Myeloma Society Annual Meeting in Toronto, Canada. The abstract, titled "3D Telomere P
2025-09-19 8:30 AM EDT | Telo Genomics Corp.
Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
White Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that it has received an Issue Notification from the European Patent Office and has been granted European Patent No. 4338791 which became effective September 17, 2025. The newly issued European patent strengthens Envoy Medical's global patent portfolio followin
Biotechnology, Healthcare and Hospitals
2025-09-19 8:00 AM EDT | Envoy Medical, Inc.
Izotropic Closes Non-Brokered Private Placement and Engages Awareness Consultants
British Columbia and Sacramento, California--(Newsfile Corp. - September 19, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its
2025-09-19 8:00 AM EDT | Izotropic Corporation
OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT
New York, New York--(Newsfile Corp. - September 19, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it has been invited to participate in the "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics" Spotlight Panel at
2025-09-19 7:40 AM EDT | OS Therapies
American Aires Inc. Announces Resignation of Director and Update on Annual General Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - September 18, 2025) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (the "Company") today announced that Mr. Dimitry Serov ("Mr. Serov") has resigned from the Board of Directors (the "Board") and advised that he will not be standing for re-election at the upcoming annual general meeting of shareholders (the "AGM"), scheduled for Thursday, September 18, 2025. As previously disclosed in the Company's press release dated Augu
2025-09-18 8:00 AM EDT | American Aires Inc.
Phio Pharmaceuticals to Present at the Life Sciences Future Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio today announced that Phio Pharmaceuticals is a presenting company at the Life Sciences Future Conference to be held September 25 - 26, 2025. Mr. Robert Bitterman, President and CEO of Phio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-09-18 7:45 AM EDT | Phio Pharmaceuticals Corp.
Scryb Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - September 17, 2025) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company"), is pleased to announce its intention to complete a non-brokered private placement (the "Offering") of up to 6,000,000 units of the Company (each, a "Unit") at a price of $0.10 per Unit, for gross proceeds of up to $600,000 Each Unit will consist of one common share (a "Common Share") and one half of one common share purchase warrant (each a
Biotechnology, Healthcare and Hospitals, Health
2025-09-17 4:05 PM EDT | Scryb Inc.
Hemostemix to Present at Life Science Investor Forum
Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to announce that
Biotechnology, Pharmaceuticals, Health
2025-09-17 7:52 AM EDT | Hemostemix Inc.
Kneat to Present at The Emerging Growth Conference on September 24, 2025
Limerick, Ireland--(Newsfile Corp. - September 16, 2025) - kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), a leader in digitizing and automating validation and quality processes, is pleased to announce that it will be presenting at the Emerging Growth Conference on September 24, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with Kneat's Chief Executive Officer and co-founder, Eddie Ryan, in real time.
2025-09-16 5:12 PM EDT | kneat.com, inc
IR-MED Investor Update Letter - Sept-2025
Rosh Pina, Israel--(Newsfile Corp. - September 16, 2025) - IR-MED Inc. (OTCQB: IRME) ("IR-MED" or the "Company"), a developer of non-invasive artificial intelligence (AI)-powered spectrographic technology to address critical healthcare challenges, today published an investor update. Dear Valued Investors, As we enter September 2025, in addition to Q2 financial reports and to the 8K recently published, I find
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-09-16 4:05 PM EDT | IR-MED, Inc.